Skye Bioscience, Net Income Applicable To Common Shares Over Time
| SKYE Stock | USD 2.85 0.01 0.35% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Skye Bioscience, Performance and Skye Bioscience, Correlation. Skye |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Skye Bioscience, Common and related stocks such as Protokinetix, Mymetics Corp, and Neutra Corp Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNXP | (3.5 M) | (3.5 M) | (9.4 M) | (10.9 M) | (27.6 M) | (48.1 M) | (38.8 M) | (21.1 M) | (29.4 M) | (31.1 M) | (52.2 M) | (92.3 M) | (116.9 M) | (105.2 M) | (99.9 M) |
| JAGX | (26.2 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (16.6 M) | (14.7 M) | (22 M) | (32.1 M) | (32.4 M) | (38.6 M) | (52.6 M) | (52.6 M) | (47.3 M) | (45 M) |
| RVMD | (34.9 M) | (34.9 M) | (34.9 M) | (34.9 M) | (34.9 M) | (34.9 M) | (34.9 M) | (34.9 M) | (48.8 M) | (61.9 M) | (110.4 M) | (187.1 M) | (248.7 M) | (223.8 M) | (212.6 M) |
| BDTX | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (8.9 M) | (35.3 M) | (67.3 M) | (125.6 M) | (91.2 M) | (82.1 M) | (86.2 M) |
| PASG | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (45.6 M) | (112.2 M) | (185.4 M) | (136.1 M) | (122.5 M) | (128.6 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (32.3 M) | (52.2 M) | (85.8 M) | (101.1 M) | (91 M) | (86.4 M) |
| GLUE | (92.9 M) | (92.9 M) | (92.9 M) | (92.9 M) | (92.9 M) | (92.9 M) | (92.9 M) | (92.9 M) | (92.9 M) | (92.9 M) | (35.9 M) | (74 M) | (108.5 M) | (97.7 M) | (102.5 M) |
| CABA | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (333.3 K) | (12.2 M) | (22.3 M) | (33.3 M) | (46.3 M) | (53 M) | (47.7 M) | (45.3 M) |
| LRMR | (74.3 M) | (74.3 M) | (74.3 M) | (74.3 M) | (74.3 M) | (74.3 M) | (57.9 M) | (52 M) | (11.2 M) | (23.1 M) | (42.5 M) | (50.6 M) | (35.4 M) | (40.7 M) | (42.7 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.5 M) | (52.2 M) | (105.4 M) | (190.2 M) | (36.3 M) | (133.3 M) | (120 M) | (126 M) |
Skye Bioscience, Common and related stocks such as Protokinetix, Mymetics Corp, and Neutra Corp Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Skye Bioscience, Common | SKYE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.85
Check out Skye Bioscience, Performance and Skye Bioscience, Correlation. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Skye Bioscience, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.